Earlier this month, New York State governor Andrew Cuomo did something very meaningful and unexpected. In an effort to drastically cut the rate of new infections in the state, he announced that he was backing the development of Truvada – the controversial HIV prevention pill. The pill was officially endorsed by the CDC in May, but this is the first time that a high-level elected official has recommended its use.
Currently, about 3,000 new HIV infections are reported in New York state each year. Cuomo wants to reduce that to 750 by 2020, and to do so, he has introduced a three-pronged strategy. Parts one and two focus on more HIV tests and getting more people with HIV to see physicians. But the third part, which includes making Truvada readily available, has the potential to cause a stir since some believe that an HIV-prevention pill promotes lower rates of condom use.
Luckily, a recent scientific study conducted by the University of California at San Fransisco found no link between use of the drug and condom use. More importantly, the drug has a proven track record when it comes to preventing HIV. Recent reports state that it cuts infection rates by more than 90 percent, and people who take the drug every day are 99 percent protected from the onset of infection.
Furthermore, despite its $13,000-a-year price tag, the drug is covered by most insurers. So, its continued obscurity appears to have more to do with marketing than anything else. In truth, many people who are at risk for HIV still aren’t aware of the drug’s existence. And despite the CDC’s recent backing, its manufacturer, Gilead, has yet to market the drug for HIV prevention, even though it is currently used as part of treatment regimens.
This is why Cuomo’s announcement, which took place during Pride Weekend, was so important. By backing the drug formally, and encouraging physicians to get the word out, he is helping to promote awareness and curb HIV infection rates. Naturally, there are those who think Cuomo’s announcement is part of a ploy to get votes from members of the LGBTQ community.
Given the recent decline in condom use among teens of all sexual orientations, this is certainly good news. While a drug like this does nothing to prevent the acquisition of other STIs – such as gonorrhea or chlamydia – it is important to remember that these diseases are treatable and non-fatal. Ultimately, having an HIV prevention drug available will ensure that there is a preventive measure in place that people are more likely to use.
Beside the Truvada endorsement, the state is also set to start enforcing a 2010 law that requires doctors to regularly offer HIV testing to patients between the ages of 13 and 65. And the state recently repealed a law that asked doctors and nurses to obtain written consent from patients before performing HIV tests, because the requirement acted as a barrier to testing.
As a recent article in The New York Times points out, the most notable aspect of the state’s rejuvenated approach to combating HIV is the combined economics of the strategies involved. None of these methods should lead to increased spending because they don’t include new medical breakthroughs. Instead, the state will probably end up saving money since every prevented HIV case saves about $400,000 in medical costs.
And this is just one of many HIV preventions that has been proven safe, effective, and ready to market. Between bee-venom nanoparticle treatments, vaccines, and even topical creams that have been proven to eliminate the virus, the coming decades are likely to see a severe drop in the number of deaths associated with the disease. And by mid century, who knows? The disease that became the plague of the 20th century may finally be history!
Source: theverge.com, nytimes.com



And while this does represent a major step forward in the field of piezoelectrics – a technology that could power everything from personal devices to entire communities by harnessing kinetic energy – it is also a boon for non-invasive medicine and energy self-sufficiency.
Battelle has been working on neurosensing technology for almost a decade. As Chad Bouton, the leader of the Neurobridge project at Battelle, explains:
A team led by Chad Bouton at Battelle spent nearly a decade developing the algorithms, software and sleeve. Then, just two years ago, Dr Ali Rezai and Dr Jerry Mysiw were brought on board to design the clinical trials. Burkhart became involved with the study after his doctor mentioned it to him and he learned he was an ideal candidate. He had the exact level of injury the researchers were looking for, is young and otherwise healthy, and lives close to the Ohio State University Wexner Medical Center, where the research is being conducted.
Post-surgery, Burkhart still had a lot of thinking to do, this time, in order to move his hand. As he explained:
Burkhart is confident that he can regain even more movement back from his hand, and the researchers are approved to try the technology out on four more patients. Ultimately, the system will only be workable commercially with a wireless neural implant, or an EEG headset – like the
Jack Andraka is at it again! For those who follow this blog (or subscribe to Forbes or watch TED Talks), this young man probably needs no introduction. But if not, then you might not known that Andraka is than the young man who – at 15 years of age – invented an inexpensive litmus test for detecting pancreatic cancer. This invention won him first prize at the 2012 Intel International Science and Engineering Fair (ISEF), and was followed up less than a year later with a handheld device that could detect cancer and even explosives.

As part of the project, Diggs and Andraka also developed an inexpensive water filter made out of plastic bottles. Next, they hope to do large-scale testing for their sensor in Maryland, where they live. They also want to develop a cell-phone-based sensor reader that lets users quickly evaluate water quality and post the test results online. Basically, its all part of what is fast becoming the digitization of health and medicine, where the sensors are portable and the information can be uploaded and shared.


The study was published online late last month in Lab on a Chip. The study’s senior author, Ali Khademhosseini – PhD, biomedical engineer, and director of the BWH Biomaterials Innovation Research Center – explained the challenge and their goal as follows:
They were also able to successfully embed these functional and perfusable microchannels inside a wide range of commonly used hydrogels, such as methacrylated gelatin or polyethylene glycol-based hydrogels. In the former case, the cell-laden gelatin was used to show how their fabricated vascular networks functioned to improve mass transport, cellular viability and cellular differentiation. Moreover, successful formation of endothelial monolayers within the fabricated channels was achieved.




In so doing, he demonstrated that the nervous system was like a computer terminal through which you could deliver commands to stop a problem, like acute inflammation, before it starts, or repair a body after it gets sick. His work also seemed to indicate that electricity delivered to the vagus nerve in just the right intensity and at precise intervals could reproduce a drug’s therapeutic reaction, but with greater effectiveness, minimal health risks, and at a fraction of the cost of “biologic” pharmaceuticals.
Impressive as this may seem, bioelectronics are just part of the growing discussion about neurohacking. In addition to the leaps and bounds being made in the field of brain-to-computer interfacing (and brain-to-brain interfacing), that would allow people to control machinery and share thoughts across vast distances, there is also a field of neurosurgery that is seeking to use the miracle material of grap


In the end, neuromorphic chips and technology are merely one half of the equation. In the grand scheme of things, the aim of all of this research is not only produce technology that can ensure better biology, but technology inspired by biology to create better machinery. The end result of this, according to some, is a world in which biology and technology increasingly resemble each other, to the point that they is barely a distinction to be made and they can be merged.

The more advanced myoelectric systems can even transmit sensation back to the user, using the same system of electrodes to simulate pressure sensation for the user. 








